JAK/STAT Signaling


Various ligands including cytokines (e.g. interferons and interleukins), hormones (e.g. erythropoietin and growth hormone) and their cell surface receptors activate JAK proteins, which autophosphorylate, and then phosphorylate the receptor. Subsequently, JAKs phosphorylate a specific tyrosine residue on the STAT protein, promoting dimerization via SH2 domains. The activated STATs form homo-/heterodimers and translocate to the nucleus to trigger target gene transcription. In addition, suppressors of cytokine signaling (SOCS) family inhibit receptor signaling via homologous or heterologous feedback regulation. Dysregulation in JAK/STAT signaling is associated with diseases such as atherosclerosis, immunodeficiencies and cancer.
-
B1104 AZD-92911 CitationTarget: EGFRSummary: Mutated forms EGFR inhibitor -
B1105 AZD-9291 mesylateSummary: third generation EGFRm inhibitor, oral and irreversible -
B1130 GLPG06341 CitationTarget: JAKSummary: JAK1 inhibitor -
B2283 Niclosamide3 CitationTarget: STATSummary: Inhibitor of the STAT3 signaling pathway -
B1799 NifuroxazideTarget: STATSummary: STAT inhibitor -
B1759 FlubendazoleSummary: Autophagy activator -
B6115 RG 13022Summary: EGFR tyrosine kinase inhibitor -
B6175 STA-21Summary: STAT3 inhibitor -
B7802 APTSTAT3-9RSummary: STAT3 inhibitor -
C3975 5,15-DPPSummary: STAT3 inhibitor

